Results 11 to 20 of about 4,771 (191)
Pamela B Allen, Mary Jo Lechowicz Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA Abstract: Peripheral T-cell lymphomas (PTCLs) are an aggressive and diverse group of lymphomas with a T-cell origin ...
Allen PB, Lechowicz MJ
doaj +6 more sources
Apoptotic effect of Belinostat (PXD101) on MCF-7 cancer cells [PDF]
Aim: Breast cancer continues to be the most common type of cancer among women. Recent development in epigenomics hashighlighted key mechanisms in which epigenetic regulation contributes to cancer treatment. Epigenetic modulating drugs promises novel approaches targeting cancer treatment. Belinostat is a histone deacetylase inhibitor approved by the U.S.
TUNCER, Zeliha +3 more
openaire +3 more sources
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. [PDF]
UnlabelledBelinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies.
Ling-Zhi Wang +16 more
doaj +2 more sources
Thermodynamic and transport properties of Belinostat
HDACs inhibitors, Belinostat inhibits class I HDACs, class II HDACs and class IV HDAC proteins activities. Antitumor activity of Belinostat is attributed to epi- genetic control of gene expression and inhibition of protein repression.
Narayan Gautam +4 more
doaj +4 more sources
The Development of an Effective Synthetic Route of Belinostat
A practical synthetic route of belinostat is reported. Belinostat was obtained via a five-step process starting from benzaldehyde and including addition reaction with sodium bisulfite, sulfochlorination with chlorosulfonic acid, sulfonamidation with aniline, Knoevenagel condensation, and the final amidation with hydroxylamine.
Xuefei Bao +4 more
openaire +2 more sources
Histone deacetylase inhibitors (HDACis) are drugs that target the epigenetic state of cells by modifying the compaction of chromatin through effects on histone acetylation.
Chi-Ming Chang +7 more
doaj +2 more sources
Monitoring the effect of belinostat in solid tumors by H4 acetylation [PDF]
Histone deacetylase (HDAC) inhibition is a novel entity in medical oncology, and several HDAC inhibitors are in clinical trials. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clinical indications.
Marquard, L. +5 more
core +4 more sources
Improving the Thrombocytopenia Adverse Reaction of Belinostat Using Human Serum Albumin Nanoparticles [PDF]
Jia-Yu Liu,1 Chia-Hung Yen,2,3 Ya-Fan Lin,4 Yin-Hsun Feng,5 Yi-Ping Fang1,6,7 1School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; 2Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical ...
Liu JY, Yen CH, Lin YF, Feng YH, Fang YP
doaj +1 more source
Background Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. Histone deacetylase inhibitors are a new and promising drug family with strong anticancer activity. The aim of this study was to examine the efficacy of in vitro and in
Dovzhanskiy Dmitriy I +7 more
doaj +2 more sources
Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi ...
Bodiford A, Talbott MS, Reddy NM
doaj +1 more source

